Abstract: Objective To report the experience of crizotinib treatment for anaplastic lymphoma kinase(ALK) positive non-small cell lung cancer(NSCLC) in 6 years. Methods The patient was a 35-year-old female, who was admitted to our center in December 2012 due to "right lung nodule detected by CT screening". On December 31, 2012, right supraclavicular lymph node resection biopsy was performed, and the pathology result showed low-differentiated adenocarcinoma. Then the patient was diagnosed as right lung adenocarcinoma(T4N3M0, stage Ⅲ B). FISH analysis identified ALK fusion in this patient, and then crizotinib was administered orally on February 7, 2013(250 mg twice per day). Craniocerebral metastases occurred on November 4, 2014 and February 24, 2016, respectively, and the corresponding target lesions were treated with cyberknife radiotherapy, while oral administration of crizotinib continued. Later, due to poor control of lesions, bevacizumab(400 mg) was given intermittently from October 2016 to January 2018, and crizotinib was taken orally at the same time. The patient was followed up for efficacy and related adverse reactions. After drug resistance, alectinib replaced crizotinib on May 18, 2018. By the end of September 30, 2018, no serious adverse reactions occurred. Results Oral administration of crizotinib combined local treatment was performed for 63.4 months, with the best response of PR. Conclusion For patients with ALK positive advanced non-small cell lung cancer, the first-line use of crizotinib is highly effective. After disease progression during the treatment, crizotinib combined with local treatment is still effective after reapplication.